Bronchopulmonary Dysplasia (BPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Bronchopulmonary Dysplasia (BPD) Market Outlook

Thelansis’s “Bronchopulmonary Dysplasia (BPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchopulmonary Dysplasia (BPD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bronchopulmonary Dysplasia (BPD) Overview

Bronchopulmonary dysplasia (BPD) is a prevalent complication among premature infants. It is characterized by an exaggerated inflammatory response in their underdeveloped lungs. The pathogenesis of BPD involves mechanical ventilation and oxidative stress, exacerbated by antenatal factors. This cascade increases proinflammatory cytokines and angiogenic factors, disrupting normal tissue repair and lung development. The severity of BPD is classified as mild, moderate, or severe based on oxygen requirements. Risk factors include prematurity and low birth weight. Despite advancements in neonatal care reducing mortality rates, BPD rates have persisted or even risen due to increased survival of extremely premature infants. The FDA has yet to approve any drugs specifically for pediatric BPD. It remains the most common fatal pulmonary consequence of prematurity. While no cure exists, treatment aims to mitigate lung damage and support growth. Strategies include nutritional support, respiratory assistance, and the potential use of macrolides for their anti-inflammatory properties. BPD is associated with various complications such as systemic hypertension, neurodevelopmental issues, pulmonary hypertension, and cardiac abnormalities like left ventricular hypertrophy and dysfunction.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2024–2034)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…


Read more: Bronchopulmonary Dysplasia (BPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Comments

Post a Comment